Vincent Vultaggio sold $98k of ZNTL
PAO and PFO at Zentalis Pharmaceuticals, Inc.. 40,224 shares at an average of $2.43, traded Feb 6, 2026, filed Feb 10, 2026.
Score components
- +15RoleOfficer
- +10Trade size$98k at market
- +5Share of holdings soldSold 22% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +14.6%, 3m +78.3%, 6m +71.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002018766-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 6, 2026 | SOpen-market sale Common Stock10b5-1 | -29,951 | $2.43 | $73k | 156,779 | Feb 10, 2026 |
| Feb 9, 2026 | SOpen-market sale Common Stock10b5-1 | -3,379 | $2.39 | $8,086 | 153,400 | Feb 10, 2026 |
| Feb 10, 2026 | SOpen-market sale Common Stock10b5-1 | -6,894 | $2.42 | $17k | 146,506 | Feb 10, 2026 |
Related signals
Other insiders at Zentalis Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | ZNTLbuy Zentalis Pharmaceuticals, Inc. | Walters Group owner | $15M 4,335,000 shares | +32% | |
| 30Weak | Zentalis Pharmaceuticals, Inc. | Ingmar Bruns Chief Medical Officer | $7,998 3,297 shares | -9% | |
| 40Moderate | Zentalis Pharmaceuticals, Inc. | Julia Marie Eastland CEO & President | $21k 8,755 shares | -10% | |
| 10Weak | Zentalis Pharmaceuticals, Inc. | Vincent Vultaggio PAO and PFO | $7,875 3,096 shares | -2% | |
| 50Moderate | ZNTLbuy Zentalis Pharmaceuticals, Inc. | Walters Group owner | $7.8M 6,459,973 shares | +92% | |
| 57Moderate | ZNTLsell Zentalis Pharmaceuticals, Inc. | Matrix Capital Management Company, LP owner | $10.0M 7,500,000 shares | -54% | |
| 31Weak | ZNTLbuy Zentalis Pharmaceuticals, Inc. | Scott Dunseth Myers director | $29k 21,000 shares | +8% | |
| 39Weak | Zentalis Pharmaceuticals, Inc. | Ingmar Bruns Chief Medical Officer | $46k 20,000 shares | +120% | |
| 48Moderate | Zentalis Pharmaceuticals, Inc. | Julia Marie Eastland CEO & President | $49k 28,500 shares | - | |
| 0Weak | Zentalis Pharmaceuticals, Inc. | Vincent Vultaggio Principal Accounting Officer | $5,098 1,603 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.